Novo to sell Tresiba in Europe at 60-70 percent premium over Lantus

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, will sell its long-acting insulin Tresiba in Europe at a 60-70 percent premium over rival product Lantus from France's Sanofi.

Source: Reuters: Health - February 15, 2013 Category: Consumer Health News Tags: healthNews Source Type: news